• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Economic Impact of Biosimilars

Opinion
Video

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.

Video content above is prompted by the following:

  • Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?
Related Videos
5 experts are featured in this series.
5 experts are featured in this series.
Dr Michael Bernstein
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
2 experts in this video
Gladys Antelo-Allen
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.